Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation
NCT ID: NCT01616615
Last Updated: 2015-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
190 participants
INTERVENTIONAL
2012-09-30
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages
NCT01635426
Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment
NCT01542411
Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion
NCT00959621
Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS
NCT04128956
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
NCT02409680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASPIRIN
150 mg milligram(s)/ day oral use
Aspirin
150 mg/day oral use
PLACEBO
placebo
1 capsule / day oral use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
150 mg/day oral use
placebo
1 capsule / day oral use
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single gestation
* Mean pulsatility index of the uterine arteries above the 95th percentile for our population
Exclusion Criteria
* previous history of pre-eclampsia
* Pregestational diabetes
* Systemic lupus Erythematosus
* Gastric ulcer
* Acetylsalicylic acid or lactose hypersensitivity
* Bleeding disorders
* Fetal disorders (including chromosomal abnormalities)
* Administration of low molecular weight heparin
* Concomitant treatment with aspirin
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sara Varea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Varea
Clinical Trial Manager
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
FRANCESC FIGUERAS, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Clinic of Barcelona
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Clinic of Barcelona
Barcelona, Barcelona, Spain
Institut Dexeus
Barcelona, Barcelona, Spain
Hospital Clínico Lozano Blesa
Zaragoza, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-000622-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ASAP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.